Healthcare / Drug Manufacturers - GeneralBSE
$925.95
+5.75 (+0.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-168.2M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.1B
P/E
19.9x
↓EV/EBITDA
13.9x
↑ROE
5.9%
↑Gross Margin
52.9%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+6.0%
FCF CAGR
—
FCF margin
-3.1%
FCF / Net income
-0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.57B · net income $656.8M · FCF $-269.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.57B | $8.57B | $8.01B | $7.48B | $7.20B |
| Net Income | $656.8M | $656.8M | $816.6M | $628.4M | $6.40B |
| EBITDA | $942.5M | $942.5M | $1.20B | $991.1M | $797.9M |
| EPS | 46.48 | 46.48 | 57.79 | 44.47 | 452.72 |
| Gross Margin | 52.9% | 52.9% | 54.0% | 54.5% | 51.4% |
| Operating Margin | 2.0% | 2.0% | 3.3% | 3.3% | 2.7% |
| Net Margin | 7.7% | 7.7% | 10.2% | 8.4% | 88.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 |
| Current Ratio | 5.91 | 5.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-269.5M | $-269.5M | $-168.2M | $-153.3M | $-365.1M |
| Returns | |||||
| ROE | 5.9% | 5.9% | 7.7% | 6.3% | 67.1% |
| Valuation | |||||
| P/E | 19.93 | 19.93 | 21.43 | 37.12 | 2.86 |
| EV/EBITDA | 13.91 | 13.91 | 14.71 | 23.65 | 23.17 |
| P/B | 1.17 | 1.17 | 1.64 | 2.33 | 1.92 |
| Growth & Yield | |||||
| Revenue Growth | 7.0% | 7.0% | 7.2% | 3.8% | — |
| EPS Growth | -19.6% | -19.6% | 30.0% | -90.2% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
20.9%
EPS terminal req.
$82.16
Spread vs growth
-40.5%
5Y implied EPS CAGR
16.4%
EPS terminal req.
$99.42
Spread vs growth
-36.0%
10Y implied EPS CAGR
13.2%
EPS terminal req.
$160.11
Spread vs growth
-32.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.4%
Start / end P/E
22.1x → 19.9x
EPS bridge
57.79 → 46.48
Residual
+1.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.